Autolus Therapeutics (NASDAQ:AUTL) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL - Free Report) in a research note released on Friday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

Separately, Truist Financial boosted their price objective on Autolus Therapeutics from $10.00 to $11.00 and gave the company a buy rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $8.16.

Autolus Therapeutics Trading Down 5.8 %

Shares of AUTL stock traded down $0.31 on Friday, reaching $5.02. The company had a trading volume of 1,494,200 shares, compared to its average volume of 1,547,161. The stock has a market cap of $1.33 billion, a PE ratio of -4.22 and a beta of 1.90. The company has a 50-day moving average of $6.04 and a 200-day moving average of $5.01. Autolus Therapeutics has a 12 month low of $1.61 and a 12 month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.18). Sell-side analysts anticipate that Autolus Therapeutics will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of large investors have recently bought and sold shares of the company. Nantahala Capital Management LLC boosted its position in Autolus Therapeutics by 6.6% during the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company's stock worth $18,124,000 after acquiring an additional 268,818 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $19,328,000. Perpetual Ltd boosted its holdings in shares of Autolus Therapeutics by 8.2% in the 1st quarter. Perpetual Ltd now owns 2,234,515 shares of the company's stock valued at $14,256,000 after buying an additional 169,784 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Autolus Therapeutics by 25.4% in the 3rd quarter. Affinity Asset Advisors LLC now owns 1,992,466 shares of the company's stock valued at $4,642,000 after buying an additional 403,449 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $11,793,000. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.